FIVE-FOR-CO.,-LTD.
6.3.2019 06:00:18 CET | Business Wire | Press release
Five for Co., Ltd. (Location: Chiyoda-ku Ward, Tokyo, Representative Director: Takayoshi Tanigawa) will open a VR experience entertainment facility, “VR NINJA DOJO” which provides Ninja experience for foreigners visiting Japan on Monday, March 18th, 2019 in Uchikanda, Chiyoda-ku, Tokyo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190305006076/en/
VR NINJA DOJO is an entertainment facility that provides “Ninja Experience” fusing the real and virtual world for foreigners visiting Japan. One of Japanese cultures, “Ninja”, is also literally popular as “Ninja” overseas. The facility is designed with the stylistic beauty inherent in Japan and is a space where you can feel the unique perspective of the Japan world. Also, this facility is designed with our own technology so that the third parties who do not wear a head-mount display can enjoy the virtual world as well. So, you can unite and enjoy the experience even when your group consists of two or more people. Furthermore, since we explain the operation completely in English, foreigners visiting Japan comfortably use the facility. Visitors will take the full proficiency examination to be a Ninja master through the VR experience after they had realistic discipline and training by doing physical activities.
Recently, the number of foreign visitors has been on the rise in Japan. According to Japan National Tourism Organization (JNTO), the total number of foreign visitors to Japan in 2018 exceeded 30,010,000, which is the first time ever recorded over 30 million people and is an increase of 8.7% from the previous year. It is expected that the number of foreign visitors to Japan will further increase by 2020, but there is some change in their consumption behavior. In the past, "entity-oriented consumption" such as purchasing large quantities of home appliances and cosmetics etc. was mainstream. But, as the EC industry has expanded, there is less value in traveling some places in order to purchase goods there. Instead, "situation-oriented consumption" such as taking experience type services including hot spring tours and kimono experiences is on the increase. The new facility in anticipation of the growing inbound demand provides a new entertainment that will definitely become popular among foreign visitors to Japan.
VR NINJA DOJO provides a Ninja experience, which is only available here, with the concept of “The Hospitality of Japanese Culture in both the 'real' and the 'virtual' world."
|
[Contents of the Experience] |
| The required time for a Ninja Experience is from 75 minutes to 90 minutes, and up to 10 persons in one group can participate. |
| Ninja cosplay experience |
| - Ninja discipline and training in the real and the virtual world |
| - Full proficiency examination (VR experience) |
| - VR ceremonial photograph |
| - Presentation of handscroll type certificate |
|
[Details of the Facility] |
||
|
The Name of the Facility: |
VR NINJA DOJO |
|
|
Opening Date: |
March 18th, 2019 |
|
|
Location of the Facility: |
Takebashi Bldg. 1F, 2-15-15 Uchikanda, Chiyoda-ku, |
|
| Tokyo 101-0047 | ||
|
Eligible Person for the Experience: Foreign residents and tourists in Japan |
||
|
- One accompanying Japanese person per a foreigner is free of charge. |
||
| (Ninja costume and the handscroll type certificate are not included.) | ||
|
- There is a special plan available catering to Japanese only. |
||
|
Official Site: |
||
|
[Company Profile] |
||
|
Company Name: |
Five for Co., Ltd. |
|
|
Date of Establishment: |
March 14th, 2017 |
|
|
Representative Director: |
Takayoshi Tanigawa |
|
|
Location: |
Uchikanda Chuo Bldg. 7F, 1-18-13 Uchikanda, |
|
| Chiyoda-ku, Tokyo 101-0047 | ||
|
Business Description: |
VR Entertainment Content Produce & Development |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305006076/en/
Contact:
VR NINJA DOJO PR SBY Co., Ltd. Inada / Arai (Antil Co., Ltd. Akazaki Ichika / Sato Katsuhiko / Yoshida Yusei) TEL: (+81) 3-5572-6061 FAX: (+81) 3-6685-5267 E-mail: vr_ninjadojo@vectorinc.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
